<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842683</url>
  </required_header>
  <id_info>
    <org_study_id>sdcn1802</org_study_id>
    <nct_id>NCT03842683</nct_id>
  </id_info>
  <brief_title>CGM Precision and Glycaemic Variability</brief_title>
  <official_title>Are Todays Continuous Glucose Monitoring Precise and Can They be Used to Reveal and Reduce Glycaemic Variability?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Vestergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of devices for continuous monitoring of the blood sugar is valuable for people with
      diabetes to understand their disease and to help prevent low blood sugar. Furthermore,
      continuous monitoring should be used in drug development to evaluate efficacy and safety.
      However, the devices have been criticised for being too inaccurate. This investigation sought
      to reveal the inaccuracies of current devices and to assess the subsequent usability related
      to the mentioned use cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following study is an exploratory investigation of continuous glucose monitoring based on
      data from a completed Novo Nordisk A/S clinical trial. Please refer to ClinicalTrials.gov
      Identifier: NCT02825251.

      Continuous Glucose Monitoring (CGM) provides an interstitial glucose reading every 5 minutes
      and is thus a powerful and important tool to identify glycaemic variability in people with
      diabetes. CGM is valuable for people with diabetes to understand their glucose metabolism and
      it has the potential to be used for detection and prediction of glycaemic excursions, such
      as, the potentially fatal and inevitable events of hypoglycaemia, or even as a component in
      the holy grail of diabetes technology; the artificial pancreas.

      However, CGM has been criticised for being inaccurate and unreliable, amongst others, due to
      the physiological and a device-related delay between plasma glucose (PG) and interstitial
      glucose (IG). Nevertheless, CGM keeps on being popular and in February 2017 an international
      consensus was established at the Advanced Technologies &amp; Treatments for Diabetes (ATTD)
      congress that even considers CGM data as a valuable and meaningful end point to be used in
      clinical trials of new drugs and devices for diabetes treatment where accuracy is of high
      importance.

      The above mentioned use cases entail that the CGM data are accurate. Therefore, the first
      part of this research proposal is to investigate whether the newest state-of-the-art CGM
      devices used in Novo Nordisk trials are in fact accurate. Based on these results, it is
      investigated to which degree glycaemic variability can be revealed.

      To investigate the accuracy of CGM, mean absolute relative difference (MARD) will be
      calculated and presented and the impact of the delay assessed by time shifting CGM
      measurements. Furthermore, correlation analyses, between for example, PG and first derivative
      of IG, will be performed to try to understand when CGM devices tend to measure inaccurate.
      Lastly, machine learning and/or deep learning approaches will be utilised to reveal glycaemic
      patterns and to detect/predict outcomes, such as, hypoglycaemia.

      Different glycaemic variability investigations will be undertaken:

        -  Test of PG vs IG and effect on clinical research. [analysis of differences]

        -  Correlation between PG values at bedtime and nocturnal hypoglycaemic events [correlation
           analyses]

        -  Effect of main evening meal and meal-time dose on nocturnal hypoglycaemic events
           [correlation analyses]

        -  Prediction of PG-confirmed hypoglycaemic events with CGM, dose and meal data as input
           [machine learning]

        -  The optimal dose and meal distribution and least CGM variability / eHbA1c [machine
           learning]

        -  Algorithm to suggest optimal dosing in relation to glycaemic variability [machine
           learning]

      Requested data are demographic, CGM, meal, dose and hypoglycaemia data from the following
      trial. The analyses are independent of treatment and therefore the treatment arm can be
      blinded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Actual">June 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal Time Shift of Continuous Glucose Monitoring Measurements</measure>
    <time_frame>16 weeks</time_frame>
    <description>Continuous glucose monitoring (CGM) measurements are delayed compared to blood glucose. The CGM signal is time-shifted -1 minute at a time and the mean absolute difference between CGM and blood glucose measurements are calculated at each step. The lowest mean absolute difference depicts the optimal time shift in minutes. The resultant mean absolute relative difference is provided as outcome.
Publication reference: https://doi.org/10.1177/1932296819848721</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction</measure>
    <time_frame>16 weeks</time_frame>
    <description>Area under the receiver operating characteristics curve (ROC-AUC) is a measure of the prediction capabilities of a prediction algorithm. Each point of the curve gives a sensitivity and a specificity of the prediction.
Publication reference: https://doi.org/10.1177/1932296819868727</description>
  </secondary_outcome>
  <enrollment type="Actual">472</enrollment>
  <condition>Diabetes Type 1</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with type 1 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        As copied from the original clinical trial ClinicalTrials.gov Identifier: NCT02825251

        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing the informed consent

          -  Diagnosed with T1DM (Type 1 Diabetes Mellitus) (based on clinical judgement and/or
             supported by laboratory analysis as per local guidelines) equal or above 1 year prior
             to the day of screening

          -  Using the same Medtronic pump (Minimed 530G (551/751), Paradigm Veo (554/754),
             Paradigm Revel (523/723), Paradigm (522/722)) for CSII in a basal-bolus regimen with a
             rapid acting insulin analogue for at least six months prior to screening and willing
             to stay on the same pump model throughout the trial (if the model is changed the
             change should not exceed 7 consecutive days.)

          -  HbA1c (glycosylated haemoglobin) 7.0-9.0% (53-75 mmol/mol) as assessed by central
             laboratory at screening

          -  Body mass index (BMI) below or equal to 35.0 kg/m^2 at screening

          -  Ability and willingness to take at least 3 daily meal-time insulin bolus infusions
             every day throughout the trial

        Exclusion Criteria:

          -  Any of the following: myocardial infarction, stroke, hospitalization for unstable
             angina or transient ischaemic attack within the past 180 days prior to the day of
             screening

          -  Planned coronary, carotid or peripheral artery revascularisation known on the day of
             screening

          -  History of hospitalization for ketoacidosis below or equal to 180 days prior to the
             day of screening

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 90 days before screening

          -  Any condition which, in the opinion of the Investigator, might jeopardise a Subject's
             safety or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Vestergaard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center North Denmark</affiliation>
  </overall_official>
  <reference>
    <citation>Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017 Jun;19(S3):S25-S37. doi: 10.1089/dia.2017.0035. Review.</citation>
    <PMID>28585879</PMID>
  </reference>
  <reference>
    <citation>Jensen MH, Christensen TF, Tarnow L, Seto E, Dencker Johansen M, Hejlesen OK. Real-time hypoglycemia detection from continuous glucose monitoring data of subjects with type 1 diabetes. Diabetes Technol Ther. 2013 Jul;15(7):538-43. doi: 10.1089/dia.2013.0069. Epub 2013 Apr 30.</citation>
    <PMID>23631608</PMID>
  </reference>
  <reference>
    <citation>Jensen MH, Christensen TF, Tarnow L, Mahmoudi Z, Johansen MD, Hejlesen OK. Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection. J Diabetes Sci Technol. 2013 Jan 1;7(1):135-43.</citation>
    <PMID>23439169</PMID>
  </reference>
  <reference>
    <citation>El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 Jan 28;389(10067):369-380. doi: 10.1016/S0140-6736(16)32567-3. Epub 2016 Dec 20. Erratum in: Lancet. 2017 Jan 28;389(10067):368. Lancet. 2017 Feb 4;389(10068):e2.</citation>
    <PMID>28007348</PMID>
  </reference>
  <reference>
    <citation>Rebrin K, Sheppard NF Jr, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset. J Diabetes Sci Technol. 2010 Sep 1;4(5):1087-98.</citation>
    <PMID>20920428</PMID>
  </reference>
  <reference>
    <citation>Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther. 2015 Mar;17(3):177-86. doi: 10.1089/dia.2014.0272. Epub 2014 Dec 1.</citation>
    <PMID>25436913</PMID>
  </reference>
  <reference>
    <citation>Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600. Review.</citation>
    <PMID>29162583</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <results_first_submitted>July 22, 2019</results_first_submitted>
  <results_first_submitted_qc>October 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2019</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Vestergaard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03842683/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03842683/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Glucose Monitoring Users</title>
          <description>User of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CGM Users</title>
          <description>User of CGM and CSII</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="472"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Optimal Time Shift of Continuous Glucose Monitoring Measurements</title>
        <description>Continuous glucose monitoring (CGM) measurements are delayed compared to blood glucose. The CGM signal is time-shifted -1 minute at a time and the mean absolute difference between CGM and blood glucose measurements are calculated at each step. The lowest mean absolute difference depicts the optimal time shift in minutes. The resultant mean absolute relative difference is provided as outcome.
Publication reference: https://doi.org/10.1177/1932296819848721</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGM Users</title>
            <description>User of CGM and CSII</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Time Shift of Continuous Glucose Monitoring Measurements</title>
          <description>Continuous glucose monitoring (CGM) measurements are delayed compared to blood glucose. The CGM signal is time-shifted -1 minute at a time and the mean absolute difference between CGM and blood glucose measurements are calculated at each step. The lowest mean absolute difference depicts the optimal time shift in minutes. The resultant mean absolute relative difference is provided as outcome.
Publication reference: https://doi.org/10.1177/1932296819848721</description>
          <units>Percentage point change in MARD</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.77" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction</title>
        <description>Area under the receiver operating characteristics curve (ROC-AUC) is a measure of the prediction capabilities of a prediction algorithm. Each point of the curve gives a sensitivity and a specificity of the prediction.
Publication reference: https://doi.org/10.1177/1932296819868727</description>
        <time_frame>16 weeks</time_frame>
        <population>Nine people from the original study did not have sufficient CGM, insulin, or meal data for the calculation of features.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring Users</title>
            <description>User of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction</title>
          <description>Area under the receiver operating characteristics curve (ROC-AUC) is a measure of the prediction capabilities of a prediction algorithm. Each point of the curve gives a sensitivity and a specificity of the prediction.
Publication reference: https://doi.org/10.1177/1932296819868727</description>
          <population>Nine people from the original study did not have sufficient CGM, insulin, or meal data for the calculation of features.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.74" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0</time_frame>
      <desc>This study is an observational retrospective investigation based on data collected in a previous clinical trial. For specific information about the adverse events in that trial, please refer to NCT02825251</desc>
      <group_list>
        <group group_id="E1">
          <title>CGM Users</title>
          <description>User of CGM and CSII</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Morten Hasselstrøm Jensen</name_or_title>
      <organization>Steno Diabetes Center North Denmark</organization>
      <phone>+4522226964</phone>
      <email>mhj@hst.aau.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

